A detailed history of Black Rock Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,551,510 shares of CCCC stock, worth $19.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,551,510
Previous 905,006 402.93%
Holding current value
$19.6 Million
Previous $7.39 Million 184.42%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.05 - $8.1 $14.8 Million - $29.5 Million
3,646,504 Added 402.93%
4,551,510 $21 Million
Q1 2024

May 10, 2024

SELL
$5.3 - $11.0 $4.76 Million - $9.88 Million
-898,427 Reduced 49.82%
905,006 $7.39 Million
Q4 2023

Feb 13, 2024

SELL
$1.18 - $6.03 $344,447 - $1.76 Million
-291,905 Reduced 13.93%
1,803,433 $10.2 Million
Q3 2023

Nov 13, 2023

BUY
$1.81 - $3.89 $15,882 - $34,134
8,775 Added 0.42%
2,095,338 $3.9 Million
Q2 2023

Aug 11, 2023

SELL
$2.75 - $3.77 $4.43 Million - $6.07 Million
-1,610,179 Reduced 43.56%
2,086,563 $5.74 Million
Q1 2023

May 12, 2023

BUY
$3.1 - $9.02 $234,387 - $681,993
75,609 Added 2.09%
3,696,742 $11.6 Million
Q4 2022

Feb 13, 2023

BUY
$5.42 - $10.24 $848,560 - $1.6 Million
156,561 Added 4.52%
3,621,133 $21.4 Million
Q3 2022

Nov 14, 2022

BUY
$8.03 - $12.77 $537,801 - $855,257
66,974 Added 1.97%
3,464,572 $30.4 Million
Q2 2022

Aug 12, 2022

BUY
$5.06 - $26.46 $1.3 Million - $6.82 Million
257,608 Added 8.2%
3,397,598 $25.6 Million
Q1 2022

May 12, 2022

SELL
$19.99 - $33.23 $5.32 Million - $8.84 Million
-265,992 Reduced 7.81%
3,139,990 $76.2 Million
Q4 2021

Feb 10, 2022

BUY
$29.39 - $46.86 $7.31 Million - $11.7 Million
248,775 Added 7.88%
3,405,982 $110 Million
Q3 2021

Nov 09, 2021

BUY
$35.91 - $50.5 $18.8 Million - $26.5 Million
524,783 Added 19.94%
3,157,207 $141 Million
Q2 2021

Aug 11, 2021

BUY
$30.39 - $42.18 $80 Million - $111 Million
2,632,424 New
2,632,424 $99.6 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $210M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.